We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > STI-1499

News List

Sorrento gets US FDA nod for Phase 1 clinical trial of neutralising antibody in COVID-19 patients expresspharma
September 18, 2020
Sorrento had earlier informed that COVI-GUARD (STI-1499) demonstrated 100 per cent in vitro neutralizing effect against SARS-CoV-2.
Sorrento to Acquire SmartPharm contractpharma
July 27, 2020
Gains non-viral DNA and RNA gene delivery platforms for COVID-19 and rare diseases.
Potential Anti-SARS-CoV-2 Antibody Able to Inhibit In Vitro Virus Infection in Preclinical Studies americanpharmaceuticalreview
May 19, 2020
Sorrento Therapeutics announced anti-SARS-CoV-2 antibody, STI-1499, demonstrated 100% inhibition of SARS-CoV-2 virus infection in an in vitro virus infection experiment at a very low antibody concentration.
Sorrento’s antibody completely blocks Covid-19 in-vitro pharmaceutical-technology
May 19, 2020
Sorrento Therapeutics has reported that its Covid-19 therapeutic antibody candidate, STI-1499, can completely block the viral infection in-vitro during preclinical studies.